{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:19Z","timestamp":1786118779493,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,31]]},"DOI":"10.1097\/qad.0b013e32825a69a8","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T05:00:32Z","timestamp":1184302832000},"page":"1547-1554","source":"Crossref","is-referenced-by-count":16,"title":["Virologic efficacy of boosted double versus boosted single protease inhibitor therapy"],"prefix":"10.1097","volume":"21","author":[{"given":"Maya L","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yon","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Jeffrey","family":"Fessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00126334-200408010-00005","article-title":"The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir","volume":"36","author":"Corbett","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/00002030-200307250-00018","article-title":"Lopinavir\/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy","volume":"17","author":"la Porte","year":"2003","journal-title":"AIDS"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1310\/HAG3-8YA5-UDQC-36NX","article-title":"Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients","volume":"6","author":"Smith","year":"2005","journal-title":"HIV Clin Trials"},{"key":"R4-7-20210130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hernan","year":"2000","journal-title":"Epidemiology"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Recommendations of the International AIDS Society-USA Panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R9-7-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jspi.2004.06.060","article-title":"Why prefer double robust estimates? Illustration with causal point treatment studies","volume":"129","author":"Neugebauer","year":"2005","journal-title":"J Stat Plan Inference"},{"key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2202\/1544-6115.1069","article-title":"Deletion\/substitution\/addition algorithm in learning with applications in genomics","volume":"3","author":"Sinisi","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"R13-7-20210130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.288.2.169","article-title":"Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial","volume":"288","author":"Hammer","year":"2002","journal-title":"JAMA"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1310\/7LYW-GQFF-WPRQ-K3QW","article-title":"Clinical impact of double protease inhibitor boosting with lopinavir\/ritonavir and amprenavir as part of salvage antiretroviral therapy","volume":"4","author":"Loutfy","year":"2003","journal-title":"HIV Clin Trials"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200707310-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:41:36Z","timestamp":1786034496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200707310-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32825a69a8","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,31]]}}}